Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Roche's Tecentriq Steals Lead In Triple-Negative Breast Cancer

Mar 09 2019

• By Emily Hayes

Breast Cancer Awareness: Microscopic image (photomicrograph) of core biopsy for infiltrating (invasive) ductal carcinoma, detected by screening mammogram. H & E stain.

Related Content

Roche Remains Positive After Tecentriq Triple-Negative Breast Cancer Data

Oct 22 2018

Roche's Tecentriq Becomes Second In PD-1/L1 Family To Gain First-Line Lung Cancer Approval

Dec 07 2018

Genentech’s Tecentriq Stakes New Claim With FDA Lung Cancer Approval

Oct 19 2016

Early Tecentriq OK Gives Roche/Genentech Jump On PD-L1 Bladder Cancer Market

May 19 2016

Merck's Keytruda Offers Hope And Risk In Early Breast Cancer

Jun 06 2017

Related Companies

Roche Holding AG

Bristol Myers Squibb Company

Merck & Co., Inc.

Additional Topics

Approvals ImmunoOncology Regulation Cancer BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window